American Society of Hematology
Preparing for ASH 2025: Pharma’s role in hematology innovation
As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...
J&J presents positive phase 3 results for Darzalex Faspro in smouldering multiple myeloma
The early precursor of active disease accounts for 15% of all newly-diagnosed multiple myeloma cases
Roche announces five-year results for Polivy combination in diffuse large B-cell lymphoma
Approximately 160,000 cases of the aggressive blood cancer are diagnosed globally every year
Sanofi’s rilzabrutinib shows promise in phase 3 immune thrombocytopenia study
Approximately 9.5 per 100,000 people in the US are affected by the rare autoimmune disorder
Regeneron shares positive late-stage results for poze-cemdi in rare blood disorder PNH
Paroxysmal nocturnal haemoglobinuria affects up to 1.5 people per million in the US
Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
The company will present 90 abstracts from across a wide range of haematologic diseases, including results from three pivotal studies in lymphoma and haemophilia
Mixed news for gene therapies at ASH conference
GSK unveils successful trial, but there was disappointing news for Bluebird
Novel therapies for blood cancers showcased at ASH
Novartis' lead CAR-T therapy is one of those in the spotlight